Purified pyocin, administered parenterally to mice infected with sensitive strains of Pseudomonas aeruginosa, afforded significant protection against two of the three strains studied.
The potential of bacteriocins as chemotherapeutic agents appears not to have been investigated. Their selectivity and the danger of sensitization associated with their protein nature are factors which would discourage such studies with organisms for which efficient antibiotics are available. Pseudomonas aeruginosa, resistant to most antibiotics and disinfectants, has acquired a prominent position as an agent of nosocomial infection in recent years (6) , and it was considered that an examination of pyocin as a possible chemotherapeutic agent might be useful.
Pyocin 78-C2, prepared from mitomycin Cinduced cultures of P. aeruginosa ( were left as controls while 10 were treated in one of the following schedules: (i) pyocin (0.1 ml) intravenously immediately after infection; (ii) pyocin (0.1 ml) intravenously immediately after infection and repeated 24 hr later; (iii) pyocin (0.1 ml) intraperitoneally immediately after infection; (iv) pyocin (0.1 ml) intravenously 6 hr after infection; (v) pyocin (0.2 ml) intravenously 24 hr after infection; (vi) glucose 10% (0.1 ml) intravenously immediately after infection.
Schedule vi was included to detect any effect of glucose in the pyocin on the survival of infected mice. Times of death were noted to the nearest 24 hr, the experiments being terminated after 14 days.
Analysis of results by Wilcoxon's stratified ranking test (7) demonstrated significant protection (P < 1%) against strain 320 in schedules i and iv and against 325 in schedules i and ii. No effect could be proved in any schedule with strain 327, although the latter remained sensitive to pyocin in vitro throughout the experiments. Glucose (schedule vi) increased the death rate of infected mice, particularly with strain 320, so that the full protective effect of pyocin was probably not achieved in these experiments. Failure of intraperitoneal treatment (schedule iii) was not unexpected.
Infection was initiated by washed cells since pyocine was not expected to neutralize the extracellular products from which P. aeruginosa derives much of its pathogenicity (1). The resulting large doses of bacteria provided a test for pyocin of greater severity than would exist in the normal situation where fewer cells would be involved in a localized infection. The results obtained are encouraging and warrant further study. 
